Immunology follow-up note

**(Use gender-specific pronouns (he/him or she/her) based on the patient's gender. Only use they/them if gender information is unavailable.)** **Summary of Clinical Problems and Diagnoses** Patient presents with a history of recurrent upper respiratory infections and suspected primary immunodeficiency. Confirmed diagnosis of Common Variable Immunodeficiency (CVID). **Current Therapy** Patient is currently receiving intravenous immunoglobulin (IVIG) infusions every three weeks at a dose of 400mg/kg. He is also taking prophylactic antibiotics, trimethoprim-sulfamethoxazole, 80/400mg, twice weekly. **Summary of Progress Since Last Visit** Patient reports a decrease in the frequency of upper respiratory infections since the last visit. He has experienced one mild cold in the past three months, which resolved without complications. No hospitalisations since the last visit. **History of Infections** Patient has a history of recurrent sinopulmonary infections, including pneumonia and sinusitis, prior to diagnosis and treatment with IVIG. He has also had a history of oral thrush. **Satisfaction with Current Therapy and Adverse Reactions** Patient reports being satisfied with the current therapy. He denies any significant side effects from IVIG infusions. He reports mild fatigue on the day of the infusion. **Results of Investigations** Recent laboratory results show an improvement in IgG levels, now at 850 mg/dL (normal range: 700-1600 mg/dL). Flow cytometry shows stable B-cell and T-cell counts. **Advice Regarding Treatment** Advised the patient to continue with the current IVIG regimen and prophylactic antibiotics. Discussed the importance of adherence to the treatment plan. Reviewed signs and symptoms of infection and when to seek medical attention. Shared decision-making regarding the timing of the next infusion. **New Investigations Ordered** No new investigations ordered. **Summary of Progress** Overall, the patient is showing good progress with a reduction in the frequency of infections and improved IgG levels. His current clinical status is stable. **Interval to Next Follow-up** Next follow-up appointment scheduled in three months, on 1 February 2025.